Document_and_Entity_Informatio
| Document and Entity Information | 3 Months Ended | |
| Mar. 31, 2014 | 5-May-14 | |
| Document and Entity Information [Abstract] | ' | ' |
| Entity Registrant Name | 'XOMA Corp | ' |
| Entity Central Index Key | '0000791908 | ' |
| Current Fiscal Year End Date | '--12-31 | ' |
| Entity Well-known Seasoned Issuer | 'No | ' |
| Entity Voluntary Filers | 'No | ' |
| Entity Current Reporting Status | 'Yes | ' |
| Entity Filer Category | 'Accelerated Filer | ' |
| Entity Common Stock, Shares Outstanding | ' | 106,898,733 |
| Document Fiscal Year Focus | '2014 | ' |
| Document Fiscal Period Focus | 'Q1 | ' |
| Document Type | '10-Q | ' |
| Amendment Flag | 'true | ' |
| Amendment Description | 'We are filing this Amended Quarterly Report on Form 10-Q/A (the “Amended Filingâ€) to correct an error in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2014, which was filed with the Securities and Exchange Commission (“SECâ€) on May 7, 2014 (the “Original Filingâ€), to amend and restate our diluted loss per share for the quarter ended March 31, 2014, as discussed below and in Note 2 to the accompanying restated condensed consolidated financial statements. | ' |
| Document Period End Date | 31-Mar-14 | ' |
CONDENSED_CONSOLIDATED_BALANCE
| CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (USD $) | Mar. 31, 2014 | Dec. 31, 2013 | |
| In Thousands, unless otherwise specified | |||
| Current assets: | ' | ' | |
| Cash and cash equivalents | $73,706 | $101,659 | [1] |
| Short-term investments | 19,996 | 19,990 | [1] |
| Trade and other receivables, net | 4,312 | 3,781 | [1] |
| Prepaid expenses and other current assets | 2,558 | 1,630 | [1] |
| Total current assets | 100,572 | 127,060 | [1] |
| Property and equipment, net | 6,028 | 6,456 | [1] |
| Other assets | 1,029 | 1,266 | [1] |
| Total assets | 107,629 | 134,782 | [1] |
| Current liabilities: | ' | ' | |
| Accounts payable | 8,851 | 9,616 | [1] |
| Accrued and other liabilities | 4,895 | 9,934 | [1] |
| Deferred revenue | 2,158 | 2,218 | [1] |
| Interest bearing obligation - current | 4,085 | 5,835 | [1] |
| Accrued Interest on interest bearing obligations - current | 264 | 2,042 | [1] |
| Total current liabilities | 20,253 | 29,645 | [1] |
| Deferred revenue - long-term | 3,636 | 4,105 | [1] |
| Interest bearing obligations - long-term | 34,658 | 35,150 | [1] |
| Contingent warrant liabilities | 47,342 | 69,869 | [1] |
| Total liabilities | 105,889 | 138,769 | [1] |
| Stockholders' equity (deficit): | ' | ' | |
| Common stock, $0.0075 par value, 138,666,666 shares authorized, 106,885,926 and 105,386,216 shares outstanding at March 31, 2014 and December 31, 2013, respectively | 799 | 787 | [1] |
| Additional paid-in capital | 1,086,798 | 1,076,403 | [1] |
| Accumulated comprehensive income (loss) | 6 | -1 | [1] |
| Accumulated deficit | -1,085,863 | -1,081,176 | [1] |
| Total stockholders' equity (deficit) | 1,740 | -3,987 | [1] |
| Total liabilities and stockholders' equity (deficit) | $107,629 | $134,782 | [1] |
| [1] | (Note 1) The condensed consolidated balance sheet as of December 31, 2013 has been derived from the audited consolidated financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013. | ||
CONDENSED_CONSOLIDATED_BALANCE1
| CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical) (USD $) | Mar. 31, 2014 | Dec. 31, 2013 |
| Stockholders' equity (deficit): | ' | ' |
| Common stock, par value (in dollars per share) | $0.01 | $0.01 |
| Common stock, shares authorized (in shares) | 138,666,666 | 138,666,666 |
| Common stock, shares outstanding (in shares) | 106,885,926 | 105,386,216 |
CONDENSED_CONSOLIDATED_STATEME
| CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (unaudited) (USD $) | 3 Months Ended | |
| In Thousands, except Per Share data, unless otherwise specified | Mar. 31, 2014 | Mar. 31, 2013 |
| Revenues: | ' | ' |
| License and collaborative fees | $964 | $399 |
| Contract and other | 2,446 | 9,054 |
| Total revenues | 3,410 | 9,453 |
| Operating expenses: | ' | ' |
| Research and development | 21,546 | 16,636 |
| Selling, general and administrative | 5,254 | 4,124 |
| Restructuring | 84 | 17 |
| Total operating expenses | 26,884 | 20,777 |
| Loss from operations | -23,474 | -11,324 |
| Other income (expense): | ' | ' |
| Interest expense | -1,125 | -1,172 |
| Other (expense) income | -90 | 449 |
| Revaluation of contingent warrant liabilities | 20,002 | -12,840 |
| Net loss | -4,687 | -24,887 |
| Basic net loss per share of common stock (in dollars per shares) | ($0.04) | ($0.30) |
| Diluted net loss per share of common stock - restated for the three months ended March 31, 2014 (in dollars per share) | ($0.21) | ($0.30) |
| Shares used in computing basic net loss per share of common stock (in shares) | 106,158 | 82,595 |
| Shares used in computing diluted net loss per share of common stock - restated for the three months ended March 31, 2014 (in shares) | 115,524 | 82,595 |
| Other comprehensive loss: | ' | ' |
| Net loss | -4,687 | -24,887 |
| Net unrealized gains on available-for-sale securities | 7 | 3 |
| Comprehensive loss | ($4,680) | ($24,884) |
CONDENSED_CONSOLIDATED_STATEME1
| CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) (USD $) | 3 Months Ended | ||
| In Thousands, unless otherwise specified | Mar. 31, 2014 | Mar. 31, 2013 | |
| Cash flows from operating activities: | ' | ' | |
| Net loss | ($4,687) | ($24,887) | |
| Adjustments to reconcile net loss to net cash used in operating activities: | ' | ' | |
| Depreciation | 477 | 780 | |
| Common stock contribution to 401(k) | 870 | 828 | |
| Stock-based compensation expense | 3,924 | 1,619 | |
| Accrued interest on interest bearing obligations | -1,764 | 1,586 | |
| Revaluation of contingent warrant liabilities | -20,002 | 12,840 | |
| Amortization of debt discount, final payment fee on debt, and debt issuance costs | 674 | 603 | |
| Unrealized gain on foreign currency exchange | -66 | -515 | |
| Unrealized loss on foreign exchange options | 122 | 189 | |
| Other non-cash adjustments | 1 | -4 | |
| Changes in assets and liabilities: | ' | ' | |
| Trade and other receivables, net | -530 | 1,997 | |
| Prepaid expenses and other assets | -923 | -802 | |
| Accounts payable and accrued liabilities | -5,721 | -7,097 | |
| Deferred revenue | -524 | -111 | |
| Other liabilities | -51 | -1,554 | |
| Net cash used in operating activities | -28,200 | -14,528 | |
| Cash flows from investing activities: | ' | ' | |
| Proceeds from maturities of investments | 0 | 20,000 | |
| Net purchase of property and equipment | -49 | -498 | |
| Net cash (used in) provided by investing activities | -49 | 19,502 | |
| Cash flows from financing activities: | ' | ' | |
| Proceeds from issuance of common stock, net of issuance costs | 3,053 | 60 | |
| Proceeds from the exercise of warrants | 35 | 0 | |
| Principal payments of debt | -2,792 | 0 | |
| Net cash provided by financing activities | 296 | 60 | |
| Net (decrease) increase in cash and cash equivalents | -27,953 | 5,034 | |
| Cash and cash equivalents at the beginning of the period | 101,659 | [1] | 45,345 |
| Cash and cash equivalents at the end of the period | 73,706 | 50,379 | |
| Cash paid for: | ' | ' | |
| Interest | 2,194 | 333 | |
| Non-cash investing and financing activities: | ' | ' | |
| Reclassification of contingent warrant liability to equity upon exercise of warrants | -2,525 | 0 | |
| Interest added to principal balances on long-term debt | $0 | $313 | |
| [1] | (Note 1) The condensed consolidated balance sheet as of December 31, 2013 has been derived from the audited consolidated financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013. | ||
Description_of_Business
| Description of Business | 3 Months Ended |
| Mar. 31, 2014 | |
| Description of Business [Abstract] | ' |
| Description of Business | ' |
| 1. Description of Business | |
| XOMA Corporation ("XOMA" or the "Company"), a Delaware corporation combines a portfolio of late-stage clinical programs and research activities to develop innovative therapeutic antibodies that it intends to commercialize. XOMA focuses its scientific research on allosteric modulation, which offers opportunities for new classes of therapeutic antibodies to treat a wide range of human diseases. XOMA is developing its lead product candidate gevokizumab (IL-1 beta modulating antibody) with Servier through a global Phase 3 clinical development program and ongoing proof-of-concept studies in other IL-1-mediated diseases. XOMA's scientific research also has produced the XMet platform, which consists of three classes of preclinical antibodies, including selective insulin receptor modulators that could offer new approaches in the treatment of diabetes. The Company's products are presently in various stages of development and are subject to regulatory approval before they can be commercially launched. | |
Basis_of_Presentation_and_Sign
| Basis of Presentation and Significant Accounting Policies | 3 Months Ended |
| Mar. 31, 2014 | |
| Basis of Presentation and Significant Accounting Policies [Abstract] | ' |
| Basis of Presentation and Significant Accounting Policies | ' |
| 2. Basis of Presentation and Significant Accounting Policies | |
| Basis of Presentation | |
| The condensed consolidated financial statements include the accounts of XOMA and its subsidiaries. All intercompany accounts and transactions among consolidated entities were eliminated during consolidation. The unaudited financial statements were prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. As permitted under those rules certain footnotes or other financial information can be condensed or omitted. These financial statements and related disclosures have been prepared with the assumption that users of the interim financial information have read or have access to the audited financial statements for the preceding fiscal year. Accordingly, these statements should be read in conjunction with the audited consolidated financial statements and related notes included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2013, filed with the U.S. Securities and Exchange Commission ("SEC") on March 12, 2014. | |
| In management's opinion, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting only of normal recurring adjustments, which are necessary to present fairly the Company's consolidated financial position as of March 31, 2014, the consolidated results of the Company's operations and the Company's cash flows for the three months ended March 31, 2014 and 2013. The interim results of operations are not necessarily indicative of the results that may be expected for the full fiscal year or any other periods. | |
| Restatement | |
| The Company has determined that a restatement is required to the previously reported diluted loss per share of common stock for the three months ended March 31, 2014, specifically as it relates to an error in the calculation and disclosure of diluted earnings (loss) per share as it applies to our March 2012 warrants. The correction has no impact on the Company's condensed consolidated balance sheets, net loss or comprehensive loss, basic loss per share of common stock or the condensed consolidated statements of cash flows as previously reported for the three months ended March 31, 2014. | |
| In March 2012, in connection with an underwritten offering, the Company issued five-year warrants to purchase 14,834,577 shares of the Company’s common stock at an exercise price of $1.76 per share (the "2012 Warrants"). These warrants were recorded as a liability at fair value and are revalued at each reporting period until the earlier of the exercise of the warrants, at which time the liability will be reclassified to stockholders' equity, or expiration of the warrants. The revaluation gain or loss is recorded to the statement of comprehensive loss. The calculation of diluted loss per share requires that, if the average market price of the shares underlying the Company’s 2012 Warrants for the reporting period is greater than the exercise price of the 2012 Warrants and if the presumed exercise of such securities would be dilutive to loss per share for the period, then the reported net loss used in the calculation of diluted net loss per share must be adjusted to remove the change in fair value for the period of the 2012 Warrants from the numerator of the net loss calculation. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any, under the treasury stock method. The Company failed to make the adjustments to the diluted loss per share calculation for the three months ended March 31, 2014. No other previously reported periods require correction. | |
| The impact of the restatement in the reported diluted loss per share of common stock for the three months ended March 31, 2014 is an increase of $(0.17) over the previously reported $(0.04) diluted loss per share, resulting in a corrected diluted loss per share of $(0.21) for the three months ended March 31, 2014. | |
| Use of Estimates | |
| The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an on-going basis, management evaluates its estimates including, but not limited to, those related to contingent warrant liabilities, revenue recognition, research and development expense, long-lived assets, derivative instruments and stock-based compensation. The Company bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ significantly from these estimates, such as the Company's billing under government contracts. Under the Company's contracts with the National Institute of Allergy and Infectious Diseases ("NIAID"), a part of the National Institutes of Health ("NIH"), the Company bills using NIH provisional rates and thus are subject to future audits at the discretion of NIAID's contracting office. These audits can result in an adjustment to revenue previously reported. | |
| Reclassifications | |
| Certain reclassifications of prior period amounts have been made to the financial statements and accompanying notes to conform to the current period presentation. Prior period presentations of net product sales has been reclassified into contract and other revenue, and cost of sales has been reclassified into research and development expense, because the net product sales were not material for all periods presented. These reclassifications had no impact on the Company's previously reported net loss or cash flows. | |
| Concentration of Risk | |
| Cash equivalents and receivables are financial instruments, which potentially subject the Company to concentrations of credit risk, as well as liquidity risk for certain cash equivalents such as money market funds. The Company has not encountered such issues during 2014. | |
| The Company has not experienced any significant credit losses and does not generally require collateral on receivables. For the three months ended March 31, 2014, three customers represented 47%, 40%, and 15% of total revenue and 57%, 28%, and 12% of the accounts receivable balance. | |
| For the three months ended March 31, 2013, two customers represented 79% and 18% of total revenues. As of December 31, 2013, there were receivables outstanding from these two customers representing 73% and 13% of the accounts receivable balance. |
Condensed_Consolidated_Financi
| Condensed Consolidated Financial Statement Detail | 3 Months Ended | ||||||||
| Mar. 31, 2014 | |||||||||
| Condensed Consolidated Financial Statement Detail [Abstract] | ' | ||||||||
| Condensed Consolidated Financial Statement Detail | ' | ||||||||
| 3. Condensed Consolidated Financial Statement Detail | |||||||||
| Net Loss Per Share of Common Stock | |||||||||
| Basic net loss per share of common stock is based on the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share of common stock is based on the weighted average number of shares outstanding during the period, adjusted to include the assumed conversion of certain stock options, restricted stock units ("RSUs"), and warrants for common stock. The calculation of diluted loss per share also requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the warrants and the presumed exercise of such securities are dilutive to earnings (loss) per share for the period, adjustments to net income or net loss used in the calculation are required to remove the change in fair value of the warrants for the period. Likewise, adjustments to the denominator are required to reflect the related dilutive shares. The Company failed to make such adjustments to the diluted earnings (loss) per share calculations for the period presented. | |||||||||
| Potentially dilutive securities are excluded from the calculation of loss per share of common stock if their inclusion is anti-dilutive. The following table shows the total outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share (in thousands): | |||||||||
| Three Months Ended March 31, | |||||||||
| 2014 | 2013 | ||||||||
| Common stock options and restricted stock units | 5,732 | 6,459 | |||||||
| Warrants for common stock - restated | 1,910 | 16,176 | |||||||
| Total | 7,642 | 22,635 | |||||||
| For the three months ended March 31, 2014, the following is a reconciliation of the numerators and denominators of the basic and diluted net loss per share of common stock (in thousands): | |||||||||
| 3 Months Ended March 31, 2014 | |||||||||
| Numerator | |||||||||
| Net loss originally reported | (4,687 | ) | |||||||
| Correction - removal of revaluation of contingent warrant liabilities | (19,534 | ) | |||||||
| Numerator for use in diluted loss per share of common stock - restated | (24,221 | ) | |||||||
| Denominator | |||||||||
| Weighted average shares outstanding used for diluted net loss per share of common stock originally reported | 106,158 | ||||||||
| Correction - effect of dilutive warrants | 9,366 | ||||||||
| Denominator for use in diluted loss per share of common stock - restated | 115,524 | ||||||||
| For the three months ended March 31, 2013, all potentially dilutive securities outstanding were considered anti-dilutive, and therefore the calculation of basic and diluted net loss per share was the same. | |||||||||
| Cash and Cash Equivalents | |||||||||
| At March 31, 2014, cash and cash equivalents consisted of demand deposits of $10.1 million and money market funds of $63.6 million with maturities of less than 90 days at the date of purchase. At December 31, 2013, cash and cash equivalents consisted of demand deposits of $18.9 million and money market funds of $82.8 million with maturities of less than 90 days at the date of purchase. | |||||||||
| Short-term Investments | |||||||||
| At both March 31, 2014 and December 31, 2013, short-term investments consisted of U.S. treasury securities of $20.0 million with maturities of greater than 90 days and less than one year from the date of purchase. | |||||||||
| Foreign Exchange Options | |||||||||
| The Company holds debt and may incur revenue and expenses denominated in foreign currencies, which exposes it to market risk associated with foreign currency exchange rate fluctuations between the U.S. dollar and the Euro. The Company is required in the future to make principal and accrued interest payments in Euros on its €15.0 million loan from Servier (See Note 5: Long-Term Debt and Other Arrangements). In order to manage its foreign currency exposure related to these payments, in May 2011, the Company entered into two foreign exchange option contracts to buy €1.5 million and €15.0 million in January 2014 and January 2016, respectively. By having these option contracts in place, the Company's foreign exchange rate risk is reduced if the U.S. dollar weakens against the Euro. However, if the U.S. dollar strengthens against the Euro, the Company is not required to exercise these options, but will not receive any refund on premiums paid. | |||||||||
| Upfront premiums paid on these foreign exchange option contracts totaled $1.5 million. The fair values of these option contracts are revalued at each reporting period and are estimated based on pricing models using readily observable inputs from actively quoted markets. The fair values of these option contracts are included in other assets on the condensed consolidated balance sheet and changes in fair value on these contracts are included in other income (expense) on the condensed consolidated statements of comprehensive loss. | |||||||||
| The January 2014 foreign exchange option expired in January 2014 without being exercised. The January 2016 foreign exchange option was revalued at March 31, 2014 and had a fair value of $0.2 million. The Company recognized losses of $0.1 million and $0.2 million related to the revaluation for the three months ended March 31, 2014 and 2013, respectively. | |||||||||
| Accrued Liabilities | |||||||||
| Accrued liabilities consisted of the following at March 31, 2014 and December 31, 2013 (in thousands): | |||||||||
| March 31, | December 31, | ||||||||
| 2014 | 2013 | ||||||||
| Accrued payroll and other benefits | $ | 2,401 | $ | 3,009 | |||||
| Accrued management incentive compensation | 1,050 | 4,386 | |||||||
| Other | 1,444 | 2,539 | |||||||
| Total | $ | 4,895 | $ | 9,934 | |||||
| Contingent Warrant Liabilities | |||||||||
| In March 2012, in connection with an underwritten offering, the Company issued five-year warrants to purchase 14,834,577 shares of XOMA's common stock at an exercise price of $1.76 per share. These warrants contain provisions that are contingent on the occurrence of a change in control, which would conditionally obligate the Company to repurchase the warrants for cash in an amount equal to their fair value using the Black-Scholes Option Pricing Model (the "Black-Scholes Model") on the date of such change in control. Due to these provisions, the Company is required to account for the warrants issued in March 2012 as a liability at fair value. In addition, the estimated liability related to the warrants is required to be revalued at each reporting period until the earlier of the exercise of the warrants, at which time the liability will be reclassified to stockholders' equity, or expiration of the warrants. At December 31, 2013, the fair value of the warrant liability was estimated to be $68.7 million using the Black-Scholes Model. The Company revalued the warrant liability at March 31, 2014 using the Black-Scholes Model and recorded the $19.5 million decrease in the fair value as a gain in the revaluation of contingent warrant liabilities line of its condensed consolidated statements of comprehensive loss. The Company also reclassified $2.5 million from contingent warrant liabilities to equity on its condensed consolidated balance sheets due to the exercise of warrants. As of March 31, 2014, 12,109,418 of these warrants were outstanding and had a fair value of $46.6 million. This decrease in liability is due primarily to the decrease in the market price of XOMA's common stock at March 31, 2014 compared to December 31, 2013. | |||||||||
| In February 2010, in connection with an underwritten offering, the Company issued five-year warrants to purchase 1,260,000 shares of XOMA's common stock at an exercise price of $10.50 per share. In June 2009, the Company issued warrants to certain institutional investors as part of a registered direct offering. These warrants represent the right to acquire an aggregate of up to 347,826 shares of XOMA's common stock over a five year period beginning December 11, 2009 at an exercise price of $19.50 per share. These warrants contain provisions that are contingent on the occurrence of a change in control, which would conditionally obligate the Company to repurchase the warrants for cash in an amount equal to their fair value using the Black-Scholes Model on the date of such change in control. Due to these provisions, the Company is required to account for the warrants issued in February 2010 and June 2009 as liabilities at fair value. At December 31, 2013, the fair value of the warrant liability was estimated to be $1.2 million using the Black-Scholes Model. The Company revalued the warrant liability at March 31, 2014 using the Black-Scholes Model and recorded the $0.5 million decrease in the fair value as a gain in the revaluation of contingent warrant liabilities line of our condensed consolidated statements of comprehensive loss. As of March 31, 2014, all of these warrants were outstanding and had an aggregate fair value of approximately $0.7 million. | |||||||||
Fair_Value_Measurements
| Fair Value Measurements | 3 Months Ended | ||||||||||||||||
| Mar. 31, 2014 | |||||||||||||||||
| Fair Value Measurements [Abstract] | ' | ||||||||||||||||
| Fair Value Measurements | ' | ||||||||||||||||
| 4. Fair Value Measurements | |||||||||||||||||
| Fair value is defined as the price that would be received from selling an asset or the amount that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company applies accounting standards, which establish a framework for measuring fair value and a fair value hierarchy that prioritizes the inputs used in valuation techniques. Accounting standards describe a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following: | |||||||||||||||||
| Level 1 – Quoted prices in active markets for identical assets or liabilities. | |||||||||||||||||
| Level 2 – Observable inputs other than quoted prices in active markets for similar assets or liabilities. | |||||||||||||||||
| Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of assets and liabilities, therefore requiring in entity to develop its own assumptions. | |||||||||||||||||
| The following tables set forth the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2014 and December 31, 2013. | |||||||||||||||||
| Financial assets and liabilities carried at fair value as of March 31, 2014 and December 31, 2013 were classified as follows (in thousands): | |||||||||||||||||
| Fair Value Measurements at March 31, 2014 Using | |||||||||||||||||
| Quoted Prices in | Significant Other Observable Inputs | Significant Unobservable Inputs | |||||||||||||||
| Active Markets for | |||||||||||||||||
| Identical Assets | |||||||||||||||||
| (Level 1) | (Level 2) | (Level 3) | Total | ||||||||||||||
| Assets: | |||||||||||||||||
| Money market funds (1) | $ | 63,561 | $ | - | $ | - | $ | 63,561 | |||||||||
| U.S. treasury securities | 19,996 | - | - | 19,996 | |||||||||||||
| Foreign exchange options | - | 239 | - | 239 | |||||||||||||
| Total | $ | 83,557 | $ | 239 | $ | - | $ | 83,796 | |||||||||
| Liabilities: | |||||||||||||||||
| Contingent warrant liabilities | $ | - | $ | - | $ | 47,342 | $ | 47,342 | |||||||||
| Fair Value Measurements at December 31, 2013 Using | |||||||||||||||||
| Quoted Prices in | Significant Other Observable Inputs | Significant Unobservable Inputs | |||||||||||||||
| Active Markets for | |||||||||||||||||
| Identical Assets | |||||||||||||||||
| (Level 1) | (Level 2) | (Level 3) | Total | ||||||||||||||
| Assets: | |||||||||||||||||
| Money market funds (1) | $ | 82,759 | $ | - | $ | - | $ | 82,759 | |||||||||
| U.S. treasury securities | 19,990 | - | - | 19,990 | |||||||||||||
| Foreign exchange options | - | 361 | - | 361 | |||||||||||||
| Total | $ | 102,749 | $ | 361 | $ | - | $ | 103,110 | |||||||||
| Liabilities: | |||||||||||||||||
| Contingent warrant liabilities | $ | - | $ | - | $ | 69,869 | $ | 69,869 | |||||||||
| -1 | Included in cash and cash equivalents | ||||||||||||||||
| The fair value of the foreign exchange options at March 31, 2014 and December 31, 2013 was determined using readily observable market inputs from actively quoted markets obtained from various third-party data providers. These inputs, such as spot rate, forward rate and volatility have been derived from readily observable market data, meeting the criteria for Level 2 in the fair value hierarchy. | |||||||||||||||||
| The fair value of the contingent warrant liabilities at March 31, 2014 and December 31, 2013 was determined using the Black-Scholes Model, which requires unobservable inputs such as the expected term of the warrants, volatility and risk-free interest rate. These inputs are subjective and generally require significant analysis and judgment to derive. | |||||||||||||||||
| The fair value of the contingent warrant liabilities was estimated using the following range of assumptions at March 31, 2014 and December 31, 2013: | |||||||||||||||||
| March 31, | December 31, | ||||||||||||||||
| 2014 | 2013 | ||||||||||||||||
| Expected volatility | 74.2% - 88.4 | % | 66.1% - 86.6 | % | |||||||||||||
| Risk-free interest rate | 0.1% - 0.9 | % | 0.1% - 0.8 | % | |||||||||||||
| Expected term | 0.7 - 2.9 years | 0.9 - 3.2 years | |||||||||||||||
| The following table provides a summary of changes in the fair value of the Company’s Level 3 financial liabilities for the three months ended March 31, 2014 (in thousands): | |||||||||||||||||
| Contingent warrant liabilities | March 31, | ||||||||||||||||
| 2014 | |||||||||||||||||
| Balance at December 31, 2013 | $ | 69,869 | |||||||||||||||
| Reclassification of contingent warrant liability to equity upon exercise of warrants | (2,525 | ) | |||||||||||||||
| Net increase in fair value of contingent warrant liabilities upon revaluation | (20,002 | ) | |||||||||||||||
| Balance at March 31, 2014 | $ | 47,342 | |||||||||||||||
| The net decrease of $20.0 million in the estimated fair value of the contingent warrant liabilities was recognized as a gain in the revaluation of contingent warrant liabilities line of the condensed consolidated statements of comprehensive loss for the three months ended March 31, 2014. | |||||||||||||||||
| For the three months ended March 31, 2013, the Company recognized a net increase of $12.8 million in the estimated fair value of the contingent warrant liabilities as a loss in the revaluation of contingent warrant liabilities line of the condensed consolidated statements of comprehensive loss. | |||||||||||||||||
LongTerm_Debt_and_Other_Financ
| Long-Term Debt and Other Financings | 3 Months Ended | ||||||||
| Mar. 31, 2014 | |||||||||
| Long-Term Debt and Other Financings [Abstract] | ' | ||||||||
| Long-Term Debt and Other Financings | ' | ||||||||
| 5. Long-Term Debt and Other Financings | |||||||||
| Novartis Note | |||||||||
| In May 2005, the Company executed a secured note agreement with Novartis (then Chiron Corporation), which is due and payable in full in June 2015. Under the note agreement, the Company borrowed semi-annually to fund up to 75% of the Company's research and development and commercialization costs under its collaboration arrangement with Novartis, not to exceed $50 million in aggregate principal amount. Interest on the principal amount of the loan accrues at six-month LIBOR plus 2%, which was equal to 2.35% at March 31, 2014, and is payable semi-annually in June and December of each year. Additionally, the interest rate resets in June and December of each year. At the Company's election, the semi-annual interest payments can be added to the outstanding principal amount, in lieu of a cash payment, as long as the aggregate principal amount does not exceed $50 million. The Company has made this election for all interest payments thus far. Loans under the note agreement are secured by the Company's interest in its collaboration with Novartis, including any payments owed to it thereunder. | |||||||||
| At March 31, 2014 and December 31, 2013, the outstanding principal balance under this note agreement was $13.0 million and $14.8 million, respectively. Pursuant to the terms of the arrangement as restructured in November 2008, the Company will not make any additional borrowings under the Novartis note. Pursuant to the its obligations under the collaboration with Novartis, in January 2014, the Company made a payment, equal to 25 percent of a $7.0 million milestone it received in December 2013, or $1.75 million, toward its outstanding debt obligation to Novartis. | |||||||||
| Servier Loan | |||||||||
| In December 2010, in connection with the license and collaboration agreement entered into with Servier, the Company executed a loan agreement with Servier (the "Servier Loan Agreement"), which provided for an advance of up to €15.0 million. The loan was fully funded in January 2011, with the proceeds converting to approximately $19.5 million. The loan is secured by an interest in XOMA's intellectual property rights to all gevokizumab indications worldwide, excluding certain rights in the U.S. and Japan. Interest is calculated at a floating rate based on a Euro Inter-Bank Offered Rate ("EURIBOR") and subject to a cap. The interest rate is reset semi-annually in January and July of each year. The interest rate for the initial interest period was 3.22% and was reset semi-annually ranging from 2.33% to 3.83%. Interest for the six-month period from January 2014 through July 2014 was reset to 2.39%. Interest is payable semi-annually; however, the Servier Loan Agreement provides for a deferral of interest payments over a period specified in the agreement. During the deferral period, accrued interest was added to the outstanding principal amount for the purpose of interest calculation for the next six-month interest period. On the repayment commencement date, all unpaid and accrued interest was paid to Servier and thereafter, all accrued and unpaid interest shall be due and payable at the end of each six-month period. In January 2014, the Company paid $1.9 million in accrued interest to Servier. | |||||||||
| The loan matures in 2016; however, after a specified period prior to final maturity, the loan is to be repaid (i) at Servier's option, by applying up to a significant percentage of any milestone or royalty payments owed by Servier under the Company's collaboration agreement and (ii) using a significant percentage of any upfront, milestone or royalty payments the Company receives from any third party collaboration or development partner for rights to gevokizumab in the U.S. and/or Japan. In addition, the loan becomes immediately due and payable upon certain customary events of default. At both March 31, 2014 and December 31, 2013, the outstanding principal balance under this loan was $20.6 million using the March 31, 2014 Exchange Rate of 1.3752 and the December 31, 2013 Exchange Rate of 1.3766. For the three months ended March 31, 2013, the Company recorded an unrealized foreign exchange gain of $0.6 million related to the re-measurement of the loan. There was an immaterial re-measurement of the loan for the three months ended March 31, 2014. | |||||||||
| The loan has a stated interest rate lower than the market rate based on comparable loans held by similar companies, which represents additional value to the Company. The Company recorded this additional value as a discount to the face value of the loan amount, resulting in a fair value of $8.9 million. The fair value of this discount, which was determined using a discounted cash flow model, represents the differential between the stated terms and rates of the loan, and market rates. Based on the association of the loan with the collaboration arrangement, the Company recorded the offset to this discount as deferred revenue. | |||||||||
| The loan discount is amortized under the effective interest method over the expected five-year life of the loan. The Company recorded non-cash interest expense of $0.5 million and $0.4 million in the three months ended March 31, 2014 and 2013, respectively, resulting from the amortization of the loan discount. At March 31, 2014 and December 31, 2013, the net carrying value of the loan was $17.0 million and $16.5 million, respectively. For the three months ended March 31, 2013, the Company recorded an unrealized foreign exchange loss of $0.2 million related to the re-measurement of the loan discount. There was an immaterial re-measurement of the loan discount for the three months ended March 31, 2014. | |||||||||
| The Company believes realization of the benefit and the associated deferred revenue is contingent on the loan remaining outstanding over the five-year contractual term of the loan. If the Company were to stop providing service under the collaboration arrangement and the arrangement is terminated, the maturity date of the loan would be accelerated and a portion of measured benefit would not be realized. As the realization of the benefit is contingent, in part, on the provision of future services, the Company is recognizing the deferred revenue over the expected five-year life of the loan. The deferred revenue is amortized under the effective interest method, and the Company recorded $0.5 million and $0.4 million of related non-cash revenue during the three months ended March 31, 2014 and 2013, respectively. | |||||||||
| General Electric Capital Corporation Term Loan | |||||||||
| In December 2011, the Company entered into a loan agreement (the "GECC Loan Agreement") with General Electric Capital Corporation ("GECC"), under which GECC agreed to make a term loan in an aggregate principal amount of $10 million (the "Term Loan") to the Company, and upon execution of the GECC Loan Agreement, GECC funded the Term Loan. As security for its obligations under the GECC Loan Agreement, the Company granted a security interest in substantially all of its existing and after-acquired assets, excluding its intellectual property assets (such as those relating to its gevokizumab and anti-botulism products). The Term Loan accrued interest at a fixed rate of 11.71% per annum and was to be repaid over a period of 42 consecutive equal monthly installments of principal and accrued interest and was due and payable in full on June 15, 2015. The Company incurred debt issuance costs of approximately $1.3 million in connection with the Term Loan and was required to pay a final payment fee equal to $500,000 on the maturity date, or such earlier date as the Term Loan is paid in full. The debt issuance costs and final payment fee were being amortized and accreted, respectively, to interest expense over the term of the Term Loan using the effective interest method. | |||||||||
| In connection with the GECC Loan Agreement, the Company issued to GECC unregistered warrants that entitle GECC to purchase up to an aggregate of 263,158 unregistered shares of XOMA common stock at an exercise price equal to $1.14 per share. These warrants are exercisable immediately and have a five-year term. The Company allocated the aggregate proceeds of the GECC Term Loan between the warrants and the debt obligation based on their relative fair values. The fair value of the warrants issued to GECC was determined using the Black-Scholes Model. The warrants' fair value of $0.2 million was recorded as a discount to the debt obligation and was being amortized over the term of the loan using the effective interest method. | |||||||||
| In September 2012, The Company entered into an amendment to the GECC Loan Agreement providing for an additional term loan in the amount of $4.6 million, increasing the term loan obligation to $12.5 million (the "Amended Term Loan") and providing for an interest-only monthly repayment period following the effective date of the amendment through March 1, 2013, at a stated interest rate of 10.9% per annum. Thereafter, the Company is obligated to make monthly principal payments of $347,222, plus accrued interest, over a 27-month period commencing on April 1, 2013, and through June 15, 2015, at which time the remaining outstanding principal amount of $3.1 million, plus accrued interest, is due. The Company incurred debt issuance costs of approximately $0.2 million and is required to make a final payment fee in the amount of $875,000 on the date upon which the outstanding principal amount is required to be repaid in full. This final payment fee replaced the original final payment fee of $500,000. The debt issuance costs and final payment fee are being amortized and accreted, respectively, to interest expense over the term of the Amended Term Loan using the effective interest method. | |||||||||
| In connection with the amendment, on September 27, 2012 the Company issued to GECC unregistered stock purchase warrants, which entitle GECC to purchase up to an aggregate of 39,346 shares of XOMA common stock at an exercise price equal to $3.54 per share. These warrants are exercisable immediately and have a five-year term. The warrants' fair value of $0.1 million was recorded as a discount to the debt obligation and is being amortized over the term of the loan using the effective interest method. The warrants are classified in permanent equity on the consolidated balance sheets. | |||||||||
| The Amended Term Loan does not change the remaining terms of the GECC Loan Agreement. The GECC Loan Agreement contains customary representations and warranties and customary affirmative and negative covenants, including restrictions on the ability to incur indebtedness, grant liens, make investments, dispose of assets, enter into transactions with affiliates and amend existing material agreements, in each case subject to various exceptions. In addition, the GECC Loan Agreement contains customary events of default that entitle GECC to cause any or all of the indebtedness under the GECC Loan Agreement to become immediately due and payable. The events of default include any event of default under a material agreement or certain other indebtedness. | |||||||||
| The Company may prepay the Amended Term Loan voluntarily in full, but not in part, and any voluntary and certain mandatory prepayments are subject to a prepayment premium of 3% in the first year after the effective date of the loan amendment, 2% in the second year and 1% thereafter, with certain exceptions. The Company will also be required to pay the $875,000 final payment fee in connection with any voluntary or mandatory prepayment. On the effective date of the loan amendment, the Company paid an accrued final payment fee in the amount of $0.2 million relating to the original final payment fee of $500,000. | |||||||||
| At March 31, 2014 and December 31, 2013, the outstanding principal balance under the Amended Term Loan was $8.3 million and $9.4 million, respectively. | |||||||||
| Interest Expense | |||||||||
| Interest expense and amortization of debt issuance costs and discounts, recorded as other expense in the condensed consolidated statements of comprehensive loss for the three months ended March 31, 2014 and 2013 are shown below (in thousands): | |||||||||
| Three Months Ended March 31, | |||||||||
| 2014 | 2013 | ||||||||
| Interest expense | |||||||||
| Servier loan | $ | 587 | $ | 525 | |||||
| GECC term loan | 448 | 545 | |||||||
| Novartis note | 77 | 91 | |||||||
| Other | 13 | 11 | |||||||
| Total interest expense | $ | 1,125 | $ | 1,172 | |||||
Income_Taxes
| Income Taxes | 3 Months Ended |
| Mar. 31, 2014 | |
| Income Taxes [Abstract] | ' |
| Income Taxes | ' |
| 6. Income Taxes | |
| The Company did not recognize any income tax expense for the three months ended March 31, 2014 and 2013. The Company's effective tax rate will fluctuate from period to period due to several factors inherent in the nature of the Company's operations and business transactions. The factors that most significantly impact this rate include the variability of licensing transactions in foreign jurisdictions. | |
| Accounting standards provide for the recognition of deferred tax assets if realization of such assets is more likely than not. Based upon the weight of available evidence, which includes the Company's historical operating performance and carry-back potential, it has determined that total deferred tax assets should be fully offset by a valuation allowance. |
Stockbased_Compensation
| Stock-based Compensation | 3 Months Ended | ||||||||||||||||
| Mar. 31, 2014 | |||||||||||||||||
| Stock-based Compensation [Abstract] | ' | ||||||||||||||||
| Stock-based Compensation | ' | ||||||||||||||||
| 7. Stock-based Compensation | |||||||||||||||||
| In the first quarter of 2014, the Board of Directors of the Company approved grants under the Company’s Long Term Incentive Plan for an aggregate of 1,099,239 stock options and an aggregate of 972,614 RSUs to certain employees of the Company. The stock options vest monthly over four years, and the RSUs vest annually over three years, in equal increments. | |||||||||||||||||
| The Company recognizes compensation expense for all stock-based payment awards made to the Company’s employees, consultants and directors based on estimated fair values. The valuation of stock option awards is determined at the date of grant using the Black-Scholes Model. This model requires inputs such as the expected term of the option, expected volatility and risk-free interest rate. To establish an estimate of expected term, the Company considers the vesting period and contractual period of the award and its historical experience of stock option exercises, post-vesting cancellations and volatility. The estimate of expected volatility is based on the Company’s historical volatility. The risk-free rate is based on the yield available on U.S. Treasury zero-coupon issues. The forfeiture rate impacts the amount of aggregate compensation for both stock options and RSUs. To establish an estimate of forfeiture rate, the Company considers its historical experience of option forfeitures and terminations. | |||||||||||||||||
| The fair value of the stock options granted was estimated based on the following weighted average assumptions for three months ended March 31, 2014 and 2013: | |||||||||||||||||
| Three Months Ended March 31, | |||||||||||||||||
| 2014 | 2013 | ||||||||||||||||
| Dividend yield | 0 | % | 0 | % | |||||||||||||
| Expected volatility | 94 | % | 92 | % | |||||||||||||
| Risk-free interest rate | 1.73 | % | 0.78 | % | |||||||||||||
| Expected term | 5.6 years | 5.6 years | |||||||||||||||
| Stock option activity for the three months ended March 31, 2014 was as follows: | |||||||||||||||||
| Options | Weighted Average Exercise Price Per Share | Weighted Average Remaining Contractual Life (in years) | Aggregate Intrinsic Value (in thousands) | ||||||||||||||
| Options outstanding at December 31, 2013 | 7,218,241 | $ | 8.42 | 6.75 | $ | 18,213 | |||||||||||
| Granted | 1,099,239 | 8.56 | |||||||||||||||
| Exercised | (640,649 | ) | 4.72 | ||||||||||||||
| Forfeited, expired or cancelled | (116,766 | ) | 24.72 | ||||||||||||||
| Options outstanding at March 31, 2014 | 7,560,065 | $ | 8.5 | 7.14 | $ | 9,892 | |||||||||||
| Options exercisable at March 31, 2014 | 4,562,868 | $ | 10.85 | 5.95 | $ | 5,422 | |||||||||||
| The valuation of RSUs is determined at the date of grant using the closing stock price. To establish an estimate of forfeiture rate, the Company considers its historical experience of forfeitures and terminations. | |||||||||||||||||
| Unvested RSU activity for the three months ended March 31, 2014 is summarized below: | |||||||||||||||||
| Weighted- | |||||||||||||||||
| Number of | Average Grant- | ||||||||||||||||
| Shares | Date Fair Value | ||||||||||||||||
| Unvested balance at December 31, 2013 | 1,738,037 | $ | 2.73 | ||||||||||||||
| Granted | 972,614 | 8.64 | |||||||||||||||
| Vested | (478,845 | ) | 4.16 | ||||||||||||||
| Forfeited | (77,536 | ) | 2.82 | ||||||||||||||
| Unvested balance at March 31, 2014 | 2,154,270 | $ | 5.08 | ||||||||||||||
| The following table shows total stock-based compensation expense included in the condensed consolidated statements of comprehensive loss for the three months ended March 31, 2014 and 2013 (in thousands): | |||||||||||||||||
| Three Months Ended March 31, | |||||||||||||||||
| 2014 | 2013 | ||||||||||||||||
| Research and development | $ | 2,406 | $ | 997 | |||||||||||||
| Selling, general and administrative | 1,518 | 622 | |||||||||||||||
| Total stock-based compensation expense | $ | 3,924 | $ | 1,619 | |||||||||||||
Basis_of_Presentation_and_Sign1
| Basis of Presentation and Significant Accounting Policies (Policies) | 3 Months Ended |
| Mar. 31, 2014 | |
| Basis of Presentation and Significant Accounting Policies [Abstract] | ' |
| Basis of Presentation | ' |
| Basis of Presentation | |
| The condensed consolidated financial statements include the accounts of XOMA and its subsidiaries. All intercompany accounts and transactions were eliminated during consolidation. The unaudited financial statements were prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q. These financial statements and related disclosures have been prepared with the assumption that users of the interim financial information have read or have access to the audited financial statements for the preceding fiscal year. Accordingly, these statements should be read in conjunction with the audited consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013, filed with the U.S. Securities and Exchange Commission (“SEC”) on March 12, 2014. | |
| In management’s opinion, the unaudited condensed consolidated financial statements include all adjustments, consisting only of normal recurring adjustments, which are necessary to present fairly the Company’s consolidated financial position as of March 31, 2014, the consolidated results of the Company’s operations and the Company’s cash flows for the three months ended March 31, 2014 and 2013. The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year or future periods. | |
| Restatement | ' |
| Restatement | |
| The Company has determined that a restatement is required to the previously reported diluted loss per share of common stock for the three months ended March 31, 2014, specifically as it relates to an error in the calculation and disclosure of diluted earnings (loss) per share as it applies to our March 2012 warrants. The correction has no impact on the Company's condensed consolidated balance sheets, net loss or comprehensive loss, basic loss per share of common stock or the condensed consolidated statements of cash flows as previously reported for the three months ended March 31, 2014. | |
| In March 2012, in connection with an underwritten offering, the Company issued five-year warrants to purchase 14,834,577 shares of the Company’s common stock at an exercise price of $1.76 per share (the "2012 Warrants"). These warrants were recorded as a liability at fair value and are revalued at each reporting period until the earlier of the exercise of the warrants, at which time the liability will be reclassified to stockholders' equity, or expiration of the warrants. The revaluation gain or loss is recorded to the statement of comprehensive loss. The calculation of diluted loss per share requires that, if the average market price of the shares underlying the Company’s 2012 Warrants for the reporting period is greater than the exercise price of the 2012 Warrants and if the presumed exercise of such securities would be dilutive to loss per share for the period, then the reported net loss used in the calculation of diluted net loss per share must be adjusted to remove the change in fair value for the period of the 2012 Warrants from the numerator of the net loss calculation. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any, under the treasury stock method. The Company failed to make the adjustments to the diluted loss per share calculation for the three months ended March 31, 2014. No other previously reported periods require correction. | |
| The impact of the restatement in the reported diluted loss per share of common stock for the three months ended March 31, 2014 is an increase of $(0.17) over the previously reported $(0.04) diluted loss per share, resulting in a corrected diluted loss per share of $(0.21) for the three months ended March 31, 2014. | |
| Use of Estimates | ' |
| Use of Estimates | |
| The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an on-going basis, management evaluates its estimates including, but not limited to, those related to contingent warrant liabilities, revenue recognition, research and development expense, long-lived assets, derivative instruments and stock-based compensation. The Company bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ significantly from these estimates, such as the Company’s billing under government contracts. Under the Company’s contracts with the National Institute of Allergy and Infectious Diseases (“NIAID”), a part of the National Institutes of Health (“NIH”), the Company bills using NIH provisional rates and thus are subject to future audits at the discretion of NIAID’s contracting office. These audits can result in an adjustment to revenue previously reported. | |
| Reclassifications | ' |
| Reclassifications | |
| Certain reclassifications of prior period amounts have been made to the financial statements and accompanying notes to conform to the current period presentation. Prior period presentations of net product sales and royalty revenue have been reclassified into contract and other revenue because the net product sales and royalty revenue were not material for all periods presented. These reclassifications had no impact on the Company’s previously reported net loss or cash flows. | |
| Concentration of Risk | ' |
| Concentration of Risk | |
| Cash equivalents and receivables are financial instruments, which potentially subject the Company to concentrations of credit risk, as well as liquidity risk for certain cash equivalents such as money market funds. The Company has not encountered such issues during 2014. | |
| The Company has not experienced any significant credit losses and does not generally require collateral on receivables. For the three months ended March 31, 2014, three customers represented 58%, 25%, and 18% of total revenue and 67%, 15%, and 14% of the accounts receivable balance. | |
| For the three months ended March 31, 2013, two of these customers represented 40% and 49% of total revenues. As of December 31, 2013, there were receivables outstanding from these two customers representing 73% and 13% of the accounts receivable balance. |
Condensed_Consolidated_Financi1
| Condensed Consolidated Financial Statement Detail (Tables) | 3 Months Ended | ||||||||
| Mar. 31, 2014 | |||||||||
| Condensed Consolidated Financial Statement Detail [Abstract] | ' | ||||||||
| Outstanding securities considered anti-dilutive | ' | ||||||||
| The following table shows the total outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share (in thousands): | |||||||||
| Three Months Ended March 31, | |||||||||
| 2014 | 2013 | ||||||||
| Common stock options and restricted stock units | 5,732 | 6,459 | |||||||
| Warrants for common stock | 14,273 | 16,176 | |||||||
| Total | 20,005 | 22,635 | |||||||
| Reconciliation of numerators and denominators of basic and diluted net loss per share | ' | ||||||||
| For the three months ended March 31, 2014, the following is a reconciliation of the numerators and denominators of the basic and diluted net loss per share of common stock (in thousands): | |||||||||
| 3 Months Ended March 31, 2014 | |||||||||
| Numerator | |||||||||
| Net loss originally reported | (4,687 | ) | |||||||
| Correction - removal of revaluation of contingent warrant liabilities | (19,534 | ) | |||||||
| Numerator for use in diluted loss per share of common stock - restated | (24,221 | ) | |||||||
| Denominator | |||||||||
| Weighted average shares outstanding used for diluted net loss per share of common stock originally reported | 106,158 | ||||||||
| Correction - effect of dilutive warrants | 9,366 | ||||||||
| Denominator for use in diluted loss per share of common stock - restated | 115,524 | ||||||||
| Accrued liabilities | ' | ||||||||
| Accrued liabilities consisted of the following at March 31, 2014 and December 31, 2013 (in thousands): | |||||||||
| March 31, | December 31, | ||||||||
| 2014 | 2013 | ||||||||
| Accrued payroll and other benefits | $ | 2,401 | $ | 3,009 | |||||
| Accrued management incentive compensation | 1,050 | 4,386 | |||||||
| Other | 1,444 | 2,539 | |||||||
| Total | $ | 4,895 | $ | 9,934 | |||||
Fair_Value_Measurements_Tables
| Fair Value Measurements (Tables) | 3 Months Ended | ||||||||||||||||
| Mar. 31, 2014 | |||||||||||||||||
| Fair Value Measurements [Abstract] | ' | ||||||||||||||||
| Financial assets and liabilities carried at fair value | ' | ||||||||||||||||
| The following tables set forth the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2014 and December 31, 2013. | |||||||||||||||||
| Financial assets and liabilities carried at fair value as of March 31, 2014 and December 31, 2013 were classified as follows (in thousands): | |||||||||||||||||
| Fair Value Measurements at March 31, 2014 Using | |||||||||||||||||
| Quoted Prices in | Significant Other Observable Inputs | Significant Unobservable Inputs | |||||||||||||||
| Active Markets for | |||||||||||||||||
| Identical Assets | |||||||||||||||||
| (Level 1) | (Level 2) | (Level 3) | Total | ||||||||||||||
| Assets: | |||||||||||||||||
| Money market funds (1) | $ | 63,561 | $ | - | $ | - | $ | 63,561 | |||||||||
| U.S. treasury securities | 19,996 | - | - | 19,996 | |||||||||||||
| Foreign exchange options | - | 239 | - | 239 | |||||||||||||
| Total | $ | 83,557 | $ | 239 | $ | - | $ | 83,796 | |||||||||
| Liabilities: | |||||||||||||||||
| Contingent warrant liabilities | $ | - | $ | - | $ | 47,342 | $ | 47,342 | |||||||||
| Fair Value Measurements at December 31, 2013 Using | |||||||||||||||||
| Quoted Prices in | Significant Other Observable Inputs | Significant Unobservable Inputs | |||||||||||||||
| Active Markets for | |||||||||||||||||
| Identical Assets | |||||||||||||||||
| (Level 1) | (Level 2) | (Level 3) | Total | ||||||||||||||
| Assets: | |||||||||||||||||
| Money market funds (1) | $ | 82,759 | $ | - | $ | - | $ | 82,759 | |||||||||
| U.S. treasury securities | 19,990 | - | - | 19,990 | |||||||||||||
| Foreign exchange options | - | 361 | - | 361 | |||||||||||||
| Total | $ | 102,749 | $ | 361 | $ | - | $ | 103,110 | |||||||||
| Liabilities: | |||||||||||||||||
| Contingent warrant liabilities | $ | - | $ | - | $ | 69,869 | $ | 69,869 | |||||||||
| -1 | Included in cash and cash equivalents | ||||||||||||||||
| Warrant liabilities fair value assumptions | ' | ||||||||||||||||
| The fair value of the contingent warrant liabilities was estimated using the following range of assumptions at March 31, 2014 and December 31, 2013: | |||||||||||||||||
| March 31, | December 31, | ||||||||||||||||
| 2014 | 2013 | ||||||||||||||||
| Expected volatility | 74.2% - 88.4 | % | 66.1% - 86.6 | % | |||||||||||||
| Risk-free interest rate | 0.1% - 0.9 | % | 0.1% - 0.8 | % | |||||||||||||
| Expected term | 0.7 - 2.9 years | 0.9 - 3.2 years | |||||||||||||||
| Summary of changes in fair value of Level 3 financial liabilities | ' | ||||||||||||||||
| The following table provides a summary of changes in the fair value of the Company’s Level 3 financial liabilities for the three months ended March 31, 2014 (in thousands): | |||||||||||||||||
| Contingent warrant liabilities | March 31, | ||||||||||||||||
| 2014 | |||||||||||||||||
| Balance at December 31, 2013 | $ | 69,869 | |||||||||||||||
| Reclassification of contingent warrant liability to equity upon exercise of warrants | (2,525 | ) | |||||||||||||||
| Net increase in fair value of contingent warrant liabilities upon revaluation | (20,002 | ) | |||||||||||||||
| Balance at March 31, 2014 | $ | 47,342 | |||||||||||||||
LongTerm_Debt_and_Other_Financ1
| Long-Term Debt and Other Financings (Tables) | 3 Months Ended | ||||||||
| Mar. 31, 2014 | |||||||||
| Long-Term Debt and Other Financings [Abstract] | ' | ||||||||
| Interest expense and amortization of debt issuance costs | ' | ||||||||
| Interest expense and amortization of debt issuance costs and discounts, recorded as other expense in the condensed consolidated statements of comprehensive loss for the three months ended March 31, 2014 and 2013 are shown below (in thousands): | |||||||||
| Three Months Ended March 31, | |||||||||
| 2014 | 2013 | ||||||||
| Interest expense | |||||||||
| Servier loan | $ | 587 | $ | 525 | |||||
| GECC term loan | 448 | 545 | |||||||
| Novartis note | 77 | 91 | |||||||
| Other | 13 | 11 | |||||||
| Total interest expense | $ | 1,125 | $ | 1,172 | |||||
Stockbased_Compensation_Tables
| Stock-based Compensation (Tables) | 3 Months Ended | ||||||||||||||||
| Mar. 31, 2014 | |||||||||||||||||
| Stock-based Compensation [Abstract] | ' | ||||||||||||||||
| Weighted average assumptions | ' | ||||||||||||||||
| The fair value of the stock options granted was estimated based on the following weighted average assumptions for three months ended March 31, 2014 and 2013: | |||||||||||||||||
| Three Months Ended March 31, | |||||||||||||||||
| 2014 | 2013 | ||||||||||||||||
| Dividend yield | 0 | % | 0 | % | |||||||||||||
| Expected volatility | 94 | % | 92 | % | |||||||||||||
| Risk-free interest rate | 1.73 | % | 0.78 | % | |||||||||||||
| Expected term | 5.6 years | 5.6 years | |||||||||||||||
| Stock option activity | ' | ||||||||||||||||
| Stock option activity for the three months ended March 31, 2014 was as follows: | |||||||||||||||||
| Options | Weighted Average Exercise Price Per Share | Weighted Average Remaining Contractual Life (in years) | Aggregate Intrinsic Value (in thousands) | ||||||||||||||
| Options outstanding at December 31, 2013 | 7,218,241 | $ | 8.42 | 6.75 | $ | 18,213 | |||||||||||
| Granted | 1,099,239 | 8.56 | |||||||||||||||
| Exercised | (640,649 | ) | 4.72 | ||||||||||||||
| Forfeited, expired or cancelled | (116,766 | ) | 24.72 | ||||||||||||||
| Options outstanding at March 31, 2014 | 7,560,065 | $ | 8.5 | 7.14 | $ | 9,892 | |||||||||||
| Options exercisable at March 31, 2014 | 4,562,868 | $ | 10.85 | 5.95 | $ | 5,422 | |||||||||||
| Unvested RSU activity | ' | ||||||||||||||||
| Unvested RSU activity for the three months ended March 31, 2014 is summarized below: | |||||||||||||||||
| Weighted- | |||||||||||||||||
| Number of | Average Grant- | ||||||||||||||||
| Shares | Date Fair Value | ||||||||||||||||
| Unvested balance at December 31, 2013 | 1,738,037 | $ | 2.73 | ||||||||||||||
| Granted | 972,614 | 8.64 | |||||||||||||||
| Vested | (478,845 | ) | 4.16 | ||||||||||||||
| Forfeited | (77,536 | ) | 2.82 | ||||||||||||||
| Unvested balance at March 31, 2014 | 2,154,270 | $ | 5.08 | ||||||||||||||
| Stock-based compensation expense | ' | ||||||||||||||||
| The following table shows total stock-based compensation expense included in the condensed consolidated statements of comprehensive loss for the three months ended March 31, 2014 and 2013 (in thousands): | |||||||||||||||||
| Three Months Ended March 31, | |||||||||||||||||
| 2014 | 2013 | ||||||||||||||||
| Research and development | $ | 2,406 | $ | 997 | |||||||||||||
| Selling, general and administrative | 1,518 | 622 | |||||||||||||||
| Total stock-based compensation expense | $ | 3,924 | $ | 1,619 | |||||||||||||
Description_of_Business_Detail
| Description of Business (Details) | Mar. 31, 2014 |
| Antibody | |
| Description of Business [Abstract] | ' |
| Number of classes of preclinical antibodies | 3 |
Basis_of_Presentation_and_Sign2
| Basis of Presentation and Significant Accounting Policies (Details) (USD $) | 3 Months Ended | 3 Months Ended | 12 Months Ended | 3 Months Ended | 12 Months Ended | 3 Months Ended | 12 Months Ended | 3 Months Ended | |||||||||||
| Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2012 | Mar. 31, 2014 | Mar. 31, 2013 | Dec. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2014 | Dec. 31, 2013 | Mar. 31, 2014 | Dec. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2014 | |
| Customer Concentration Risk [Member] | Customer Concentration Risk [Member] | Customer Concentration Risk [Member] | Revenues [Member] | Revenues [Member] | Revenues [Member] | Revenues [Member] | Revenues [Member] | Accounts Receivable [Member] | Accounts Receivable [Member] | Accounts Receivable [Member] | Accounts Receivable [Member] | Accounts Receivable [Member] | Restate Previously Reported Diluted Loss per Share for March 2012 Warrants [Member] | Restate Previously Reported Diluted Loss per Share for March 2012 Warrants [Member] | Restate Previously Reported Diluted Loss per Share for March 2012 Warrants [Member] | ||||
| Customer | Customer | Customer | Customer Concentration Risk [Member] | Customer Concentration Risk [Member] | Customer Concentration Risk [Member] | Customer Concentration Risk [Member] | Customer Concentration Risk [Member] | Customer Concentration Risk [Member] | Customer Concentration Risk [Member] | Customer Concentration Risk [Member] | Customer Concentration Risk [Member] | Customer Concentration Risk [Member] | Restatement Adjustment [Member] | Previously Reported [Member] | |||||
| Customer 1 [Member] | Customer 1 [Member] | Customer 2 [Member] | Customer 2 [Member] | Customer 3 [Member] | Customer 1 [Member] | Customer 1 [Member] | Customer 2 [Member] | Customer 2 [Member] | Customer 3 [Member] | ||||||||||
| Restatement [Abstract] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Term of warrants | '5 years | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Aggregate number of unregistered shares of common stock called by warrants (in shares) | ' | ' | 14,834,577 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Exercise price of shares purchased under warrants (in dollars per share) | ' | ' | $1.76 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Impact of restatement on the reported diluted loss per share (in dollars per share) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ($0.17) | ' |
| Diluted net loss per share of common stock (in dollars per share) | ($0.21) | ($0.30) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ($0.21) | ' | ($0.04) |
| Concentration Risk [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Number of major customers | ' | ' | ' | 3 | 2 | 2 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Concentration risk, percentage (in hundredths) | ' | ' | ' | ' | ' | ' | 47.00% | 79.00% | 40.00% | 18.00% | 15.00% | 57.00% | 73.00% | 28.00% | 13.00% | 12.00% | ' | ' | ' |
Condensed_Consolidated_Financi2
| Condensed Consolidated Financial Statement Detail (Details) | 3 Months Ended | 1 Months Ended | 3 Months Ended | 1 Months Ended | 3 Months Ended | 1 Months Ended | 3 Months Ended | 3 Months Ended | |||||||||||||||||||||||
| Mar. 31, 2014 | Mar. 31, 2013 | Dec. 31, 2013 | Mar. 31, 2012 | Feb. 28, 2010 | Mar. 31, 2014 | Dec. 31, 2013 | Feb. 28, 2010 | Mar. 31, 2012 | Mar. 31, 2014 | Mar. 31, 2014 | Dec. 31, 2013 | Mar. 31, 2012 | Jun. 30, 2009 | Mar. 31, 2014 | Jun. 30, 2009 | Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2014 | Dec. 31, 2013 | Mar. 31, 2014 | Dec. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2013 | ||
| USD ($) | USD ($) | USD ($) | USD ($) | Five year warrants issued in February 2010 [Member] | Five year warrants issued in February 2010 [Member] | Five year warrants issued in February 2010 [Member] | Five year warrants issued in February 2010 [Member] | Five year warrants issued in March 2012 [Member] | Five year warrants issued in March 2012 [Member] | Five year warrants issued in March 2012 [Member] | Five year warrants issued in March 2012 [Member] | Five year warrants issued in March 2012 [Member] | Warrants issued to private investors [Member] | Warrants issued to private investors [Member] | Warrants issued to private investors [Member] | Options Contract [Member] | Options Contract [Member] | Options Contract [Member] | Option Contract 1 [Member] | Option Contract 2 [Member] | Demand Deposits [Member] | Demand Deposits [Member] | Money Market Funds [Member] | Money Market Funds [Member] | Previously Reported [Member] | Common stock options and restricted stock units [Member] | Common stock options and restricted stock units [Member] | Warrants for common stock [Member] | Warrants for common stock [Member] | ||
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | EUR (€) | EUR (€) | EUR (€) | USD ($) | USD ($) | USD ($) | USD ($) | |||||||||||||||
| Contract | |||||||||||||||||||||||||||||||
| Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |
| Antidilutive securities excluded from computation of earnings per share (in shares) | 7,642,000 | 22,635,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 5,732,000 | 6,459,000 | 1,910,000 | 16,176,000 | |
| Numerator [Abstract] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |
| Net loss originally reported | ($4,687,000) | ($24,887,000) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |
| Correction - removal of revaluation of contingent warrant liabilities | -19,534,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |
| Numerator for use in diluted loss per share of common stock - restated | -24,221,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |
| Denominator [Abstract] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |
| Weighted average shares outstanding used for diluted net loss per share of common stock originally reported | 115,524,000 | 82,595,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 106,158,000 | ' | ' | ' | ' | |
| Correction - effect of dilutive warrants | 9,366,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |
| Denominator for use in diluted loss per share of common stock - restated | 115,524,000 | 82,595,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 106,158,000 | ' | ' | ' | ' | |
| Cash and Cash Equivalents [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |
| Cash equivalents | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 10,100,000 | 18,900,000 | 63,600,000 | 82,800,000 | ' | ' | ' | ' | ' | |
| Short-term Investments [Abstract] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |
| Short-term investments, U.S. treasury securities | 19,996,000 | ' | 19,990,000 | [1] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Derivative [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |
| Notional amount of derivative liability | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 15,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |
| Number of foreign exchange option contracts | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |
| Derivative, amount of hedged item | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,500,000 | 15,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | |
| Derivative, premiums | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,500,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |
| Derivative fair value | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 200,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |
| Derivative, loss | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 100,000 | 200,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |
| Accrued liabilities [Abstract] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |
| Accrued payroll and other benefits | 2,401,000 | ' | 3,009,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |
| Accrued management incentive compensation | 1,050,000 | ' | 4,386,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |
| Other | 1,444,000 | ' | 2,539,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |
| Total | 4,895,000 | ' | 9,934,000 | [1] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Class of Warrant or Right [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |
| Warrants outstanding (in shares) | ' | ' | ' | ' | ' | ' | ' | 1,260,000 | ' | ' | 12,109,418 | ' | 14,834,577 | ' | ' | 347,826 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |
| Exercise price (in dollars per share) | ' | ' | ' | $1.76 | $10.50 | ' | ' | ' | $1.76 | ' | ' | ' | ' | $19.50 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |
| Fair value of warrant liability | ' | ' | ' | ' | ' | ' | 1,200,000 | ' | ' | 46,600,000 | ' | 68,700,000 | ' | ' | 700,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |
| Gain (loss) on revaluation of warrant liability | ' | ' | ' | ' | ' | 500,000 | ' | ' | ' | 19,500,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |
| Warrant Term | ' | ' | ' | ' | '5 years | ' | ' | ' | '5 years | ' | ' | ' | ' | '5 years | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |
| Reclassification of warrant liability to equity | $2,500,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |
| [1] | (Note 1) The condensed consolidated balance sheet as of December 31, 2013 has been derived from the audited consolidated financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013. | ||||||||||||||||||||||||||||||
Fair_Value_Measurements_Detail
| Fair Value Measurements (Details) (USD $) | 3 Months Ended | 12 Months Ended | 3 Months Ended | 12 Months Ended | ||||||||||||||||||
| In Thousands, unless otherwise specified | Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | Dec. 31, 2013 | Mar. 31, 2014 | Dec. 31, 2013 | Mar. 31, 2014 | Dec. 31, 2013 | Mar. 31, 2014 | Dec. 31, 2013 | Mar. 31, 2014 | Dec. 31, 2013 | Mar. 31, 2014 | Dec. 31, 2013 | ||||||||
| Warrant Liabilities [Member] | Warrant Liabilities [Member] | Warrant Liabilities [Member] | Warrant Liabilities [Member] | Warrant Liabilities [Member] | Warrant Liabilities [Member] | Recurring [Member] | Recurring [Member] | Recurring [Member] | Recurring [Member] | Recurring [Member] | Recurring [Member] | Recurring [Member] | Recurring [Member] | |||||||||
| Minimum [Member] | Minimum [Member] | Maximum [Member] | Maximum [Member] | Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | Significant Other Observable Inputs (Level 2) [Member] | Significant Other Observable Inputs (Level 2) [Member] | Significant Unobservable Inputs (Level 3) [Member] | Significant Unobservable Inputs (Level 3) [Member] | |||||||||||||
| Assets: | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||||
| Money market funds | ' | ' | ' | ' | ' | ' | $63,561 | [1] | $82,759 | [1] | $63,561 | [1] | $82,759 | [1] | $0 | [1] | $0 | [1] | $0 | [1] | $0 | [1] |
| U.S. treasury securities | ' | ' | ' | ' | ' | ' | 19,996 | 19,990 | 19,996 | 19,990 | 0 | 0 | 0 | 0 | ||||||||
| Foreign exchange options | ' | ' | ' | ' | ' | ' | 239 | 361 | 0 | 0 | 239 | 361 | 0 | 0 | ||||||||
| Total | ' | ' | ' | ' | ' | ' | 83,796 | 103,110 | 83,557 | 102,749 | 239 | 361 | 0 | 0 | ||||||||
| Liabilities: | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||||
| Contingent warrant liabilities | ' | ' | ' | ' | ' | ' | 47,342 | 69,869 | 0 | 0 | 0 | 0 | 47,342 | 69,869 | ||||||||
| Fair Value Inputs, Liabilities, Quantitative Information [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||||
| Expected volatility (in hundredths) | ' | ' | 74.20% | 66.10% | 88.40% | 86.60% | ' | ' | ' | ' | ' | ' | ' | ' | ||||||||
| Risk-free interest rate (in hundredths) | ' | ' | 0.10% | 0.10% | 0.90% | 0.80% | ' | ' | ' | ' | ' | ' | ' | ' | ||||||||
| Expected term | ' | ' | '0 years 8 months 12 days | '0 years 10 months 24 days | '2 years 10 months 24 days | '3 years 2 months 12 days | ' | ' | ' | ' | ' | ' | ' | ' | ||||||||
| Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||||
| Balance, beginning of period | 69,869 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||||
| Reclassification of contingent warrant liability to equity upon exercise of warrants | -2,525 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||||
| Net increase in fair value of contingent warrant liabilities upon revaluation | -20,002 | 12,800 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||||
| Balance, end of period | $47,342 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||||
| [1] | Included in cash and cash equivalents | |||||||||||||||||||||
LongTerm_Debt_and_Other_Financ2
| Long-Term Debt and Other Financings (Details) | 3 Months Ended | 1 Months Ended | 3 Months Ended | 1 Months Ended | 3 Months Ended | 12 Months Ended | 3 Months Ended | 1 Months Ended | 3 Months Ended | 3 Months Ended | |||||||||||||
| Mar. 31, 2014 | Mar. 31, 2013 | Dec. 31, 2013 | Mar. 31, 2012 | Jan. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2013 | Dec. 31, 2013 | Jan. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2013 | Dec. 31, 2011 | Dec. 31, 2013 | Dec. 31, 2011 | Mar. 31, 2014 | Mar. 31, 2014 | Sep. 30, 2012 | Mar. 31, 2014 | Mar. 31, 2013 | Sep. 27, 2012 | Dec. 31, 2011 | Mar. 31, 2014 | Mar. 31, 2013 | |
| USD ($) | USD ($) | USD ($) | USD ($) | Novartis Note [Member] | Novartis Note [Member] | Novartis Note [Member] | Novartis Note [Member] | Servier Loan [Member] | Servier Loan [Member] | Servier Loan [Member] | Servier Loan [Member] | Servier Loan [Member] | Servier Loan [Member] | Servier Loan [Member] | Servier Loan [Member] | General Electric Capital Corporation Term Loan [Member] | General Electric Capital Corporation Term Loan [Member] | General Electric Capital Corporation Term Loan [Member] | General Electric Capital Corporation Term Loan [Member] | General Electric Capital Corporation Term Loan [Member] | Other Financings [Member] | Other Financings [Member] | |
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | EUR (€) | Minimum [Member] | Maximum [Member] | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |||||
| Installment | Installment | ||||||||||||||||||||||
| Debt Instrument [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Maturity date | ' | ' | ' | ' | ' | 30-Jun-15 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 15-Jun-15 | ' | ' | ' | ' | ' |
| Research and development expenses funded through loan facility, maximum (in hundredths) | ' | ' | ' | ' | ' | 75.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Maximum borrowing capacity under loan agreement | ' | ' | ' | ' | ' | $50,000,000 | ' | ' | ' | ' | ' | ' | ' | € 15,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Variable rate basis | ' | ' | ' | ' | ' | 'six-month LIBOR | ' | ' | ' | 'Euro Inter-Bank Offered Rate ("EURIBOR") | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Basis spread on variable rate (in hundredths) | ' | ' | ' | ' | ' | 2.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Interest rate at period end (in hundredths) | ' | ' | ' | ' | ' | 2.35% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Outstanding principal balance | ' | ' | 9,400,000 | ' | ' | 13,000,000 | ' | 14,800,000 | ' | 20,600,000 | ' | ' | ' | ' | ' | ' | ' | 8,300,000 | ' | 3,100,000 | 10,000,000 | ' | ' |
| Percentage of milestone received (in hundredths) | ' | ' | ' | ' | 25.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Milestone received under the collaboration agreement | ' | ' | ' | ' | 7,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Repayment of debt | ' | ' | ' | ' | 1,750,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Periodic Payment, Principal | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 347,222 | ' | ' | ' | ' | ' | ' |
| Proceeds from loan | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 19,500,000 | ' | ' | ' | ' | 4,600,000 | ' | ' | ' | ' | ' | ' |
| Increase (Decrease) in term loan obligation | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 12,500,000 | ' | ' | ' | ' | ' | ' |
| Initial interest rate during period (in hundredths) | ' | ' | ' | ' | ' | ' | ' | ' | ' | 3.22% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Interest rate reset semi-annually during period (in hundredths) | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2.39% | ' | ' | ' | ' | 2.33% | 3.83% | ' | ' | ' | ' | ' | ' | ' |
| Accrued interest | 1,764,000 | -1,586,000 | ' | ' | ' | ' | ' | ' | 1,900,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Unamortized discount on debt | ' | ' | ' | ' | ' | ' | ' | ' | ' | 8,900,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Unrealized foreign exchange gain (loss) | 66,000 | 515,000 | ' | ' | ' | ' | ' | ' | ' | ' | 600,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Unrealized foreign exchange loss related to re-measurement of loan discount | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 200,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Euro to US Dollar exchange rates | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1.3752 | ' | ' | 1.3766 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Amortization period for loan discount | ' | ' | ' | ' | ' | ' | ' | ' | ' | '5 years | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Amortization of debt discount | ' | ' | ' | ' | ' | ' | ' | ' | ' | 500,000 | 400,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Carrying value of the loan | ' | ' | ' | ' | ' | ' | ' | ' | ' | 17,000,000 | ' | ' | 16,500,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Recognition of deferred revenue | ' | ' | ' | ' | ' | ' | ' | ' | ' | 500,000 | 400,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Debt issuance costs | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 200,000 | 1,300,000 | ' | ' | ' | ' | ' |
| Final payment fee | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 500,000 | ' | 875,000 | ' | ' | ' |
| Fixed interest rate accrued (in hundredths) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 11.71% | ' | 10.90% | ' | ' | ' |
| Number of monthly installments | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 27 | 42 | ' | ' | ' | ' | ' |
| Prepayment premium year one (in hundredths) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 3.00% | ' | ' | ' | ' | ' |
| Prepayment premium year two (in hundredths) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2.00% | ' | ' | ' | ' | ' |
| Prepayment premium year thereafter (in hundredths) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1.00% | ' | ' | ' | ' | ' |
| Aggregate number of unregistered shares of common stock called by warrants (in shares) | ' | ' | ' | 14,834,577 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 263,158 | ' | 39,346 | ' | ' | ' |
| Warrants exercise price (in dollars per share) | ' | ' | ' | $1.76 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $1.14 | ' | $3.54 | ' | ' | ' |
| Immediate Term for warrants exercisable (in years) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '5 years | '5 years | ' | ' | ' | ' | ' |
| Fair value of warrant liability | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 200,000 | ' | 100,000 | ' | ' | ' |
| Interest expense and amortization of debt issuance costs [Abstract] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
| Interest expense | $1,125,000 | $1,172,000 | ' | ' | ' | $77,000 | $91,000 | ' | ' | $587,000 | $525,000 | ' | ' | ' | ' | ' | ' | $448,000 | $545,000 | ' | ' | $13,000 | $11,000 |
Stockbased_Compensation_Detail
| Stock-based Compensation (Details) (USD $) | 3 Months Ended | 12 Months Ended | |
| In Thousands, except Share data, unless otherwise specified | Mar. 31, 2014 | Mar. 31, 2013 | Dec. 31, 2012 |
| Stock-based awards weighted average assumptions [Abstract] | ' | ' | ' |
| Dividend yield (in hundredths) | 0.00% | 0.00% | ' |
| Expected volatility (in hundredths) | 94.00% | 92.00% | ' |
| Risk free interest rate (in hundredths) | 1.73% | 0.78% | ' |
| Expected term | '5 years 7 months 6 days | '5 years 7 months 6 days | ' |
| Stock option activity [Roll Forward] | ' | ' | ' |
| Options outstanding beginning of period (in shares) | 7,218,241 | ' | ' |
| Granted (in shares) | 1,099,239 | ' | ' |
| Exercised (in shares) | -640,649 | ' | ' |
| Forfeited, expired or cancelled (in shares) | -116,766 | ' | ' |
| Options outstanding end of period (in shares) | 7,560,065 | ' | ' |
| Options exercisable at end period (in shares) | 4,562,868 | ' | ' |
| Stock options activity, weighted average exercise price [Roll Forward] | ' | ' | ' |
| Options outstanding, beginning of period (in dollars per share) | $8.42 | ' | ' |
| Granted (in dollars per share) | $8.56 | ' | ' |
| Exercised (in dollars per share) | $4.72 | ' | ' |
| Forfeited, expired or cancelled (in dollars per share) | $24.72 | ' | ' |
| Options outstanding, end of period (in dollars per share) | $8.50 | ' | ' |
| Options exercisable weighted average exercise price (in dollars per share) | $10.85 | ' | ' |
| Additional Disclosures [Abstract] | ' | ' | ' |
| Options outstanding weighted average remaining contractual term beginning of period | '7 years 1 month 20 days | ' | '6 years 9 months |
| Options outstanding weighted average remaining contractual term end of period | '7 years 1 month 20 days | ' | '6 years 9 months |
| Options exercisable weighted average remaining contractual term | '5 years 11 months 12 days | ' | ' |
| Options outstanding, aggregate intrinsic value at beginning of period | $18,213 | ' | ' |
| Options outstanding, aggregate intrinsic value at end of period | 9,892 | ' | ' |
| Options exercisable, aggregate intrinsic value | 5,422 | ' | ' |
| Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ' | ' | ' |
| Total stock-based compensation expense | 3,924 | 1,619 | ' |
| Research and Development [Member] | ' | ' | ' |
| Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ' | ' | ' |
| Total stock-based compensation expense | 2,406 | 997 | ' |
| Selling, General and Administrative Expenses [Member] | ' | ' | ' |
| Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ' | ' | ' |
| Total stock-based compensation expense | $1,518 | $622 | ' |
| Stock Options [Member] | Director [Member] | ' | ' | ' |
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' |
| Vesting period | '4 years | ' | ' |
| Restricted Stock Units (RSUs) [Member] | ' | ' | ' |
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' |
| Vesting period | '3 years | ' | ' |
| Unvested RSU activity [Roll Forward] | ' | ' | ' |
| Unvested balance beginning of period (in shares) | 1,738,037 | ' | ' |
| Granted (in shares) | 972,614 | ' | ' |
| Vested (in shares) | -478,845 | ' | ' |
| Forfeited (in shares) | -77,536 | ' | ' |
| Unvested balance end of period (in shares) | 2,154,270 | ' | ' |
| Unvested RSU activity, weighted average grant date fair value [Roll Forward] | ' | ' | ' |
| Unvested balance, beginning of period (in dollars per share) | $2.73 | ' | ' |
| Granted (in dollars per share) | $8.64 | ' | ' |
| Vested (in dollars per share) | $4.16 | ' | ' |
| Forfeited (in dollars per share) | $2.82 | ' | ' |
| Unvested balance, end of period (in dollars per share) | $5.08 | ' | ' |
| Long Term Incentive Plan [Member] | Stock Options [Member] | ' | ' | ' |
| Stock option activity [Roll Forward] | ' | ' | ' |
| Granted (in shares) | 1,099,239 | ' | ' |
| Long Term Incentive Plan [Member] | Restricted Stock Units (RSUs) [Member] | ' | ' | ' |
| Stock option activity [Roll Forward] | ' | ' | ' |
| Granted (in shares) | 972,614 | ' | ' |